Diabetes Drug Bydureon Wins FDA Approval

Amylin's Bydureon diabetes drug has won approval from US regulators.

The US FDA approved Amylin's once-weekly diabetes drug Bydureon late Friday. 

Bydureon had twice been rejected by the FDA, with the administration seeking more data as to how the drug affects the heart despite it receiving European approval in June 2011. 

The FDA approval does, however, come with a risk evaluation and mitigation study, noting that any benefits of the drug should be put against increased risk of acute pancreatitis and the potential risk of medullary thyroid carcinoma.